Find Lurbinectedin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 497871-47-3, Pm01183, Tryptamicidin, Zepzelca, Pm-01183, Pm-1183
Molecular Formula
C41H44N4O10S
Molecular Weight
784.9  g/mol
InChI Key
YDDMIZRDDREKEP-HWTBNCOESA-N
FDA UNII
2CN60TN6ZS

Lurbinectedin
Lurbinectedin is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.
Lurbinectedin is an Alkylating Drug. The mechanism of action of lurbinectedin is as an Alkylating Activity.
1 2D Structure

Lurbinectedin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
2.1.2 InChI
InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
2.1.3 InChI Key
YDDMIZRDDREKEP-HWTBNCOESA-N
2.1.4 Canonical SMILES
CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
2.1.5 Isomeric SMILES
CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
2.2 Other Identifiers
2.2.1 UNII
2CN60TN6ZS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Pm 01183

2. Pm-01183

3. Pm01183

2.3.2 Depositor-Supplied Synonyms

1. 497871-47-3

2. Pm01183

3. Tryptamicidin

4. Zepzelca

5. Pm-01183

6. Pm-1183

7. 2cn60tn6zs

8. Pm 01183

9. Pm1183

10. [(1r,2r,3r,11s,12s,14r,26r)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] Acetate

11. Zepsyre

12. Lurbinectedin [inn]

13. Unii-2cn60tn6zs

14. Lurbinectedin [mi]

15. Lurbinectedin [usan:inn]

16. Lurbinectedin [usan]

17. Lurbinectedin [who-dd]

18. Chembl4297516

19. Schembl16152477

20. Gtpl10681

21. Dtxsid30198065

22. Lurbinectedin [orange Book]

23. Ex-a4316

24. Who 9397

25. Nsc826275

26. S9603

27. At22223

28. Cs-6323

29. Db12674

30. Nsc-826275

31. Hy-16293

32. J3.531.659k

33. J3.652.626b

34. Pm01183;pm-1183;ly-01017;ryptamicidin

35. Q27254568

36. (1'r,6r,6ar,7r,13s,14s,16r)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-6ahspiro(7,13-azano-6,16-(epithiopropanooxymethano)(1,3)dioxolo(7,8)isoquinolino(3,2-b)(3)benzazocine-20,1'-pyrido(3,4-b)indol)-5-yl Acetate

37. [(1r,2r,3r,11s,12s,14r,26r)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22

38. Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'-(1h)pyrido(3,4-b)indol)-19-one, 5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-, (1'r,6r,6ar,7r,13s,14s,16r)-

2.4 Create Date
2012-06-18
3 Chemical and Physical Properties
Molecular Weight 784.9 g/mol
Molecular Formula C41H44N4O10S
XLogP33.9
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count14
Rotatable Bond Count4
Exact Mass784.27781479 g/mol
Monoisotopic Mass784.27781479 g/mol
Topological Polar Surface Area190 Ų
Heavy Atom Count56
Formal Charge0
Complexity1530
Isotope Atom Count0
Defined Atom Stereocenter Count7
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.


Treatment of small cell lung cancer


5 Pharmacology and Biochemistry
5.1 Pharmacology

Lurbinectedin exerts its chemotherapeutic activity by covalently binding to DNA, resulting in double-strand DNA breaks and subsequent cell death. Lurbinectedin has been associated with myelosuppression, and patients receiving therapy with this agent should be closely monitored for evidence of cytopenias. Prior to beginning therapy, ensure baseline neutrophil counts are >1,500 cells/mm3 and platelet counts are >100,000/mm3. The supplementary use of granulocyte colony-stimulating factor (G-CSF) should be considered if the neutrophil count falls below 500 cells/mm3. Lurbinectedin has also been associated with hepatotoxicity. Monitor liver function tests at baseline and regular intervals throughout therapy, and consider holding, reducing, or permanently discontinuing therapy based on the severity of observed hepatotoxicity.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
LURBINECTEDIN
5.2.2 FDA UNII
2CN60TN6ZS
5.2.3 Pharmacological Classes
Alkylating Drug [EPC]; Alkylating Activity [MoA]
5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XX - Other antineoplastic agents

L01XX69 - Lurbinectedin


5.4 Absorption, Distribution and Excretion

Absorption

Following intravenous administration, the Cmax and AUC0-inf were 107 g/L and 551 g*h/L, respectively. No accumulation between dosing intervals (every 3 weeks) has been observed. No significant differences in absorption were found between special populations (e.g. based on age, sex, ethnicity, etc.), but lurbinectedin has not been studied in the setting of severe renal impairment or moderate/severe hepatic impairment.


Route of Elimination

Approximately 89% of a given dose is recovered in the feces (<0.2% unchanged) and 6% in the urine (1% unchanged).


Volume of Distribution

The steady-state volume of distribution of lurbinectedin is 504 L.


Clearance

The total plasma clearance of lurbinectedin is approximately 11 L/h.


5.5 Metabolism/Metabolites

Lurbinectedin is metabolized primarily by CYP3A4 _in vitro_, though specific data regarding its biotransformation are lacking. An N-desmethylated metabolite has been identified in canine subjects.


5.6 Biological Half-Life

The terminal half-life of lurbinectedin is 51 hours.


5.7 Mechanism of Action

Lurbinectedin is a DNA alkylating agent. It covalently binds to guanine residues in the DNA minor groove, forming adducts that bend the DNA helix towards the major groove. This process triggers a cascade of events that affect the activity of transcription factors and impairs DNA repair pathways, ultimately leading to double-strand DNA breaks and eventual cell death. Additional mechanism(s) of action include inhibition of RNA-polymerase-II activity, inactivation of Ewing Sarcoma Oncoprotein (EWS-FL11) via nuclear redistribution, and the inhibition of human monocyte activity and macrophage infiltration into tumor tissue.


API SUPPLIERS

read-more
read-more

01

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Chemwerth Compnay Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

04

PharmaMar

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

PharmaMar

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

07

BrightGene Bio-Medical Technology ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

BrightGene Bio-Medical Technology ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Wisdom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Wisdom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Xiling Lab

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Xiling Lab

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Apicore Llc

India

USDMF

arrow
Excipient World
Not Confirmed

01

Apicore Llc

India
arrow
Excipient World
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-02-28

Pay. Date : 2024-01-16

DMF Number : 39171

Submission : 2024-01-13

Status : Active

Type : II

blank

02

BPI Europe
Not Confirmed

03

BPI Europe
Not Confirmed

03

BPI Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-05-08

Pay. Date : 2024-04-18

DMF Number : 39672

Submission : 2024-03-28

Status : Active

Type : II

blank

04

Natco Pharma Ltd

India

USDMF

arrow
BPI Europe
Not Confirmed

04

BPI Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-04-23

Pay. Date : 2024-03-21

DMF Number : 37785

Submission : 2024-03-25

Status : Active

Type : II

blank

05

Pharma Mar Sa

Spain

USDMF

arrow
BPI Europe
Not Confirmed

05

BPI Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 33969

Submission : 2019-10-25

Status : Active

Type : II

blank

06

BPI Europe
Not Confirmed

06

BPI Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37624

Submission : 2023-01-18

Status : Active

Type : II

blank

07

Xiling Lab Co Ltd

China

USDMF

arrow
BPI Europe
Not Confirmed

07

BPI Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39620

Submission : 2024-09-06

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

CST
Not Confirmed
arrow
arrow
CST
Not Confirmed

LURBINECTEDIN

NDC Package Code : 42973-353

Start Marketing Date : 2023-05-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1kg/kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

02

GP PHARM SA

Spain
CST
Not Confirmed
arrow

GP PHARM SA

Spain
arrow
CST
Not Confirmed

LURBINECTEDIN

NDC Package Code : 69112-102

Start Marketing Date : 2020-06-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (4mg/8mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

03

CST
Not Confirmed
arrow
arrow
CST
Not Confirmed

LURBINECTEDIN

NDC Package Code : 54893-0508

Start Marketing Date : 2024-03-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

Bamboo US Bidco LCC

Country
CST
Not Confirmed
arrow

Bamboo US Bidco LCC

Country
arrow
CST
Not Confirmed

LURBINECTEDIN

NDC Package Code : 83703-583

Start Marketing Date : 2020-06-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (0.5mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content

Lurbinectedin

About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...

Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs to regulated markets worldwide and has exclusive partnerships for new product development, compliance support and secure supply chain logistics. ChemWerth has access to over 500 APIs and more than 30 manufacturing facilities in the US, Europe, India and China. ChemWerth acts as a regulatory agent for over 25 FDA-approved facilities and sells more than 100 products. It has established its presence in 38 countries. In 2020, ChemWerth filed its 500th DMF with the FDA.
Chemwerth Compnay Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Lurbinectedin

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Lurbinectedin

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB

04

Apicore

India
CST
Not Confirmed
arrow

Apicore

India
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full
blank

05

Apino Pharma

China
CST
Not Confirmed
arrow

Apino Pharma

China
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the...

Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the world’s leading research institutes and universities to develop cutting-edge formulations and technologies that bring value to our customers. We are committed to exploring new opportunities presented by technology, science and global best practices to provide quality products and services that meet and exceed our customers’ needs.
blank

06

CST
Not Confirmed
arrow
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals. At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.
blank

07

CST
Not Confirmed
arrow
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special gener...

BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis.
blank

08

Natco Pharma

India
CST
Not Confirmed
arrow

Natco Pharma

India
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...

NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, NATCO today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.NATCO family currently consists of more than 2500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. NATCO is well recognized for its innovation in Pharmaceutical R&D.
blank

09

CST
Not Confirmed
arrow
arrow
CST
Not Confirmed

Lurbinectedin

About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...

Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666031400,"product":"LURBINECTEDIN, BATCH NO:PD-601-010-017","address":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA","city":"VADODARA,GUJARAT","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"VIENNA","customer":"DHL GLOBAL FORWARDING ","customerCountry":"AUSTRIA","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"22000","totalValueFC":"43155.3","currency":"USD","unitRateINR":1775500,"date":"18-Oct-2022","totalValueINR":"3551000","totalValueInUsd":"43155.3","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"4894390","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA, VADODARA,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670351400,"product":"BULK DRUG-LURBINECTEDIN","address":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA","city":"VADODARA,GUJARAT","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"VIENNA","customer":"M\/S,DHL GLOBAL FORWARDING GMBH SRL","customerCountry":"AUSTRIA","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"22000","totalValueFC":"321565.4","currency":"USD","unitRateINR":1766600,"date":"07-Dec-2022","totalValueINR":"26499000","totalValueInUsd":"321565.4","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5983718","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA, VADODARA,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674066600,"product":"LURBINECTEDIN, BATCH NO:LRBN\/22\/12\/09","address":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA","city":"VADODARA,GUJARAT","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"VIENNA","customer":"M\/S DHL GLOBAL FORWARDING GMBH SRL","customerCountry":"AUSTRIA","quantity":"0.01","actualQuantity":"9.6","unit":"GMS","unitRateFc":"22000","totalValueFC":"211694.1","currency":"USD","unitRateINR":1802916.6666666667,"date":"19-Jan-2023","totalValueINR":"17308000","totalValueInUsd":"211694.1","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"7090711","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"BLOCK NO.252-253, VILLAGE DHOBIKUV A,PADRA JAMBUSAR HIGHWAY TAL PADRA, VADODARA,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695321000,"product":"LURBINECTEDIN, BATCH NO:PD-816-004-069 (BULK DRUG)","address":"PLOT 121 GIDC MAKARPURA INDL.ESTATE","city":"VADODARA","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"RK PHARMA","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"4","unit":"GMS","unitRateFc":"25000","totalValueFC":"99146.8","currency":"USD","unitRateINR":2057500,"date":"22-Sep-2023","totalValueINR":"8230000","totalValueInUsd":"99146.8","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"4096482","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"PLOT 121 GIDC MAKARPURA INDL.ESTATE, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714588200,"product":"FOC LURBINECTEDIN IMPURTIES LURBINECTEDIN REF. STD. BATCH NO. LRBN\/23\/09\/15\/RS0","address":"PLOT 121 GIDC MAKARPURA INDL.ESTATE","city":"VADODARA","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"APICORE","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"20","totalValueFC":"9.5","currency":"USD","unitRateINR":1589.0599999999999,"date":"02-May-2024","totalValueINR":"794.53","totalValueInUsd":"9.5","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"9556856","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 121 GIDC MAKARPURA INDL.ESTATE, VADODARA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1737743400,"product":"LURBINECTEDIN (FOR R&D USE) CAS NO. 497871-47-3 (0.001 KGS) LURBINECTEDIN (FOR R&D USE) CAS NO. 497871-47-3 (0.001 KGS)","address":"NIKITA BAUNGLOW, NEAR PRAGATI","city":"GUJARAT","supplier":"NINGBO SAILPHARM MEDTECH CO.,LTD","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"APOTHECON PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"6000000","totalValueFC":"6060.6","currency":"USD","unitRateINR":"522600000","date":"25-Jan-2025","totalValueINR":"522600","totalValueInUsd":"6060.6","indian_port":"Bombay Air","hs_no":"29329990","bill_no":"7998179","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"796# EAST ZHONG SHAN ROAD. NINGBO 3 15040 CHINA SDNF","customerAddress":"NIKITA BAUNGLOW, NEAR PRAGATI"}]
18-Oct-2022
25-Jan-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) is being investigated as a maintenance treatment for adults with extensive-stage small cell lung cancer.


Lead Product(s): Lurbinectedin,Atezolizumab

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Phase IIIProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 15, 2024

blank

01

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) is being investigated as a maintenance treatment for adults with extensive-stage small cell lung cancer.

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

October 15, 2024

blank

Details:

Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: PharmaMar

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 12, 2023

blank

02

Luye Pharma

China
arrow
BPI Europe
Not Confirmed

Luye Pharma

China
arrow
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

December 12, 2023

blank

Details:

Zepzelca (lurbinectedin) inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 03, 2023

blank

03

PharmaMar

Spain
arrow
BPI Europe
Not Confirmed

PharmaMar

Spain
arrow
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin) inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

August 03, 2023

blank

Details:

Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect the activity of DNA binding proteins, and DNA repair pathways, resulting in disruption of cell cycle and eventual cell death.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 05, 2022

blank

04

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect the activity of DNA binding proteins, and DNA repair pathways, resulting in disruption of cell cycle and eventual cell de...

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

December 05, 2022

blank

Details:

Zepzelca (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of cell cycle.


Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Phase IIIProduct Type: Cytotoxic Drug

Sponsor: PharmaMar

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 26, 2022

blank

05

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in dis...

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

October 26, 2022

blank

Details:

Cosela (trilaciclib), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.


Lead Product(s): Trilaciclib,Lurbinectedin

Therapeutic Area: Oncology Brand Name: Cosela

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 26, 2022

blank

06

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : Cosela (trilaciclib), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.

Product Name : Cosela

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 26, 2022

blank

Details:

CDK12 inhibitor demonstrates strong anti-tumor activity as single agent and in combination with a DNA damaging agent and a PARP inhibitor in models of breast, lung, and ovarian cancer.


Lead Product(s): SY-5609,Lurbinectedin,Olaparib

Therapeutic Area: Oncology Brand Name: SY-5609

Study Phase: PreclinicalProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 04, 2022

blank

07

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : CDK12 inhibitor demonstrates strong anti-tumor activity as single agent and in combination with a DNA damaging agent and a PARP inhibitor in models of breast, lung, and ovarian cancer.

Product Name : SY-5609

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 04, 2022

blank

Details:

Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: PharmaMar

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 17, 2022

blank

08

Luye Pharma

China
arrow
BPI Europe
Not Confirmed

Luye Pharma

China
arrow
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

July 17, 2022

blank

Details:

Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect activity of DNA binding proteins, including some transcription factors resulting in disruption of cell cycle and eventual cell death.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 24, 2022

blank

09

BPI Europe
Not Confirmed
BPI Europe
Not Confirmed

Details : Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect activity of DNA binding proteins, including some transcription factors resulting in disruption of cell cycle and eventual...

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

March 24, 2022

blank

Details:

Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Small Cell Lung Cancer.


Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Brand Name: Zepzelca

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Eczacıbaşı Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 22, 2021

blank

10

PharmaMar

Spain
arrow
BPI Europe
Not Confirmed

PharmaMar

Spain
arrow
BPI Europe
Not Confirmed

Lead Product(s) : Lurbinectedin

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Eczacıbaşı Group

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Sma...

Product Name : Zepzelca

Product Type : Cytotoxic Drug

Upfront Cash : Undisclosed

December 22, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

IPEC-Americas
Not Confirmed
arrow
arrow
IPEC-Americas
Not Confirmed

LURBINECTEDIN

Brand Name : ZEPZELCA

Dosage Form : POWDER;INTRAVENOUS

Dosage Strength : 4MG/VIAL

Packaging :

Approval Date : 2020-06-15

Application Number : 213702

Regulatory Info : RX

Registration Country : USA

blank

02

IPEC-Americas
Not Confirmed
arrow
arrow
IPEC-Americas
Not Confirmed

LURBINECTEDIN

Brand Name : ZEPZELCA

Dosage Form : POWDER

Dosage Strength : 4MG/VIAL

Packaging :

Approval Date :

Application Number : 2520834

Regulatory Info : Prescription

Registration Country : Canada

blank

03

Medichem S.A

Spain
BPI Europe
Not Confirmed
arrow

Medichem S.A

Spain
arrow
BPI Europe
Not Confirmed

Lurbinectedin

Brand Name :

Dosage Form : Intravenous Powder

Dosage Strength : 4MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

04

PharmaMar

Spain
IPEC-Americas
Not Confirmed
arrow

PharmaMar

Spain
arrow
IPEC-Americas
Not Confirmed

Lurbinectedinum

Brand Name : Zepzelca

Dosage Form : Dry Sub

Dosage Strength : 4mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

JAZZ

Ireland
CST
Not Confirmed
arrow

JAZZ

Ireland
arrow
CST
Not Confirmed

LURBINECTEDIN

Brand Name : ZEPZELCA

Dosage Form : POWDER;INTRAVENOUS

Dosage Strength : 4MG/VIAL

Approval Date : 2020-06-15

Application Number : 213702

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

PharmaMar AG

Spain
BPI Europe
Not Confirmed
arrow

PharmaMar AG

Spain
arrow
BPI Europe
Not Confirmed

Lurbinectedinum

Brand Name : Zepzelca

Dosage Form : Dry Sub

Dosage Strength : 4mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

BPI Europe
Not Confirmed
arrow
arrow
BPI Europe
Not Confirmed

LURBINECTEDIN

Brand Name : ZEPZELCA

Dosage Form : POWDER

Dosage Strength : 4MG/VIAL

Packaging :

Approval Date :

Application Number : 2520834

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Medichem S.A

Spain
CST
Not Confirmed
arrow

Medichem S.A

Spain
arrow
CST
Not Confirmed

Lurbinectedin

Brand Name :

Dosage Form : Intravenous Powder

Dosage Strength : 4MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

01

Medichem S.A

Spain
CST
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   

Impressions: 7437

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

#PharmaFlow by PHARMACOMPASS
24 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Bioequity Europe
Not Confirmed
arrow
Bioequity Europe
Not Confirmed

Company :

Lurbinectedin

Drug Cost (USD) : 1,637,629

Year : 2022

Prescribers : 40

Prescriptions : 120

blank

02

arrow
Bioequity Europe
Not Confirmed
arrow
Bioequity Europe
Not Confirmed

Company :

Lurbinectedin

Drug Cost (USD) : 1,211,475

Year : 2021

Prescribers : 29

Prescriptions : 87

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Zepzelca

Spain
arrow
Bioequity Europe
Not Confirmed

Brand Name : Zepzelca

Spain
arrow
Bioequity Europe
Not Confirmed

Lurbinectedin

Dosage Form : Dry Sub

Dosage Strength : 4mg

Price Per Pack (Euro) : 5512.5

Published in :

Country : Switzerland

RX/OTC/DISCN : Class A

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Zepzelca

Lurbinectedin

arrow
Bioequity Europe
Not Confirmed

Brand Name : Zepzelca

Ireland
arrow
Bioequity Europe
Not Confirmed

Lurbinectedin

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 90

2019 Revenue in Millions : 0

Growth (%) : New Launch

blank

02

Brand Name : Zepzelca

Lurbinectedin

arrow
Bioequity Europe
Not Confirmed

Brand Name : Zepzelca

Ireland
arrow
Bioequity Europe
Not Confirmed

Lurbinectedin

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 247

2020 Revenue in Millions : 90

Growth (%) : 173

blank

03

Brand Name : Zepzelca

Lurbinectedin

arrow
Bioequity Europe
Not Confirmed

Brand Name : Zepzelca

Ireland
arrow
Bioequity Europe
Not Confirmed

Lurbinectedin

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 270

2021 Revenue in Millions : 247

Growth (%) : 9

blank

04

Brand Name : Zepzelca

Lurbinectedin

arrow
Bioequity Europe
Not Confirmed

Brand Name : Zepzelca

Ireland
arrow
Bioequity Europe
Not Confirmed

Lurbinectedin

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 290

2022 Revenue in Millions : 270

Growth (%) : 7

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
IPEC-Americas
Not Confirmed

JAZZ

Ireland
arrow
IPEC-Americas
Not Confirmed

LURBINECTEDIN

US Patent Number : 7763615

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 213702

Patent Use Code : U-2836

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-13

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
BioProcess International Europe
Not Confirmed

JAZZ

Ireland
arrow
BioProcess International Europe
Not Confirmed

LURBINECTEDIN

Exclusivity Code : NCE

Exclusivity Expiration Date : 2025-06-15

Application Number : 213702

Product Number : 1

Exclusivity Details :

blank

02

arrow
BioProcess International Europe
Not Confirmed

JAZZ

Ireland
arrow
BioProcess International Europe
Not Confirmed

LURBINECTEDIN

Exclusivity Code : ODE-304

Exclusivity Expiration Date : 2027-06-15

Application Number : 213702

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 497871-47-3 / Lurbinectedin API manufacturers, exporters & distributors?

Lurbinectedin manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Lurbinectedin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lurbinectedin manufacturer or Lurbinectedin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lurbinectedin manufacturer or Lurbinectedin supplier.

PharmaCompass also assists you with knowing the Lurbinectedin API Price utilized in the formulation of products. Lurbinectedin API Price is not always fixed or binding as the Lurbinectedin Price is obtained through a variety of data sources. The Lurbinectedin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Lurbinectedin

Synonyms

497871-47-3, Pm01183, Tryptamicidin, Zepzelca, Pm-01183, Pm-1183

Cas Number

497871-47-3

Unique Ingredient Identifier (UNII)

2CN60TN6ZS

About Lurbinectedin

Lurbinectedin is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.

Lurbinectedin Manufacturers

A Lurbinectedin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lurbinectedin, including repackagers and relabelers. The FDA regulates Lurbinectedin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lurbinectedin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Lurbinectedin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Lurbinectedin Suppliers

A Lurbinectedin supplier is an individual or a company that provides Lurbinectedin active pharmaceutical ingredient (API) or Lurbinectedin finished formulations upon request. The Lurbinectedin suppliers may include Lurbinectedin API manufacturers, exporters, distributors and traders.

click here to find a list of Lurbinectedin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Lurbinectedin USDMF

A Lurbinectedin DMF (Drug Master File) is a document detailing the whole manufacturing process of Lurbinectedin active pharmaceutical ingredient (API) in detail. Different forms of Lurbinectedin DMFs exist exist since differing nations have different regulations, such as Lurbinectedin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Lurbinectedin DMF submitted to regulatory agencies in the US is known as a USDMF. Lurbinectedin USDMF includes data on Lurbinectedin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lurbinectedin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Lurbinectedin suppliers with USDMF on PharmaCompass.

Lurbinectedin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lurbinectedin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Lurbinectedin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Lurbinectedin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Lurbinectedin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lurbinectedin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Lurbinectedin suppliers with NDC on PharmaCompass.

Lurbinectedin GMP

Lurbinectedin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lurbinectedin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lurbinectedin GMP manufacturer or Lurbinectedin GMP API supplier for your needs.

Lurbinectedin CoA

A Lurbinectedin CoA (Certificate of Analysis) is a formal document that attests to Lurbinectedin's compliance with Lurbinectedin specifications and serves as a tool for batch-level quality control.

Lurbinectedin CoA mostly includes findings from lab analyses of a specific batch. For each Lurbinectedin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lurbinectedin may be tested according to a variety of international standards, such as European Pharmacopoeia (Lurbinectedin EP), Lurbinectedin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lurbinectedin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty